

## LITERATURA

1. Hájek R, Maisnar V, Minařík J, et al. Diagnostika a léčba mnohočetného myelomu. 2023. *Transfúze a hematologie dnes* 2023;29, (Suppl. 2).
2. Durie BGM, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for inmediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. *Lancet*. 2017; 89:519-527.
3. Facon T, Kumar S, Orlowski RZ, et al. Final survival analysis of daratumumab plus lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: MAIA study. *EHA Library Facon*; 421032 (2024); P968. Available from: <https://library.ehaweb.org/eha/2024/eha-2024-congress/421032/thierry.facon.final.survival.analysis.of.daratumumab.plus.lenalidomide.and.html>.
4. Facon T, Dimopoulos MA, Leleu XP, et al. Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. *N Engl J Med*. 2024 Oct 31;391(17):1597-1609. Available from: <http://doi: 10.1056/NEJMoa2400712>.
5. Sonneveld P, Dimopoulos MA, Boccadoro M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. *N Engl J Med*. 2024 Jan 25;390(4):301-313.
6. Devasia AJ, Chari A, Lancman G. Bispecific antibodies in the treatment of multiple myeloma. *Blood Cancer Journal*. 2024, 14; 158. Available from: <http://doi.org/10.1038/s41408-024-01139-y>.
7. San Miguel J, Dhakal B, Yong K, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. *N Engl J Med*. 2023;389:335-347.
8. Oncologic Drugs Advisory Committee (ODAC). i2TEAM presentation to support MRD as accelerated approval endpoint. Data from April 2024. Available from: <http://www.fda.gov>.
9. Rückert M, Azarias G, Garg M et al. Evolution of treatment patterns and survival outcomes in European Patients with multiple myeloma from 2012-2023 Through the HONEUR Federated Data Network. *Blood*. 2024;144(Supplement 1):2388-2388. Available from: <http://doi:10.1182/blood-2024-201692>.
10. Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene Autoleucel, a B-Cell maturation antigen-directed chimeric antigen receptor T-Cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A Phase 1 b/2 Open-Label Study. *The Lancet*. 2021;398(10297):314-24. Available from: [http://doi:10.1016/S0140-6736\(21\)00933-8](http://doi:10.1016/S0140-6736(21)00933-8).
11. Lin Y, Martin TG, Usmani SZ, et al. CARTITUDE-1 final results: Phase 1 b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma. *Journal of Clinical Oncology*. 2023;41(16\_suppl):8009-8009. Available from: [http://doi:10.1200/JCO.2023.41.16\\_suppl.8009](http://doi:10.1200/JCO.2023.41.16_suppl.8009).
12. Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene Autoleucel, an Anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-Year Follow-Up. *Journal of Clinical Oncology*. 2023;41(6):1265-74. Available from: <http://doi:10.1200/JCO.22.00842>.
13. Munshi NC, Anderson LD, Shah N, et al. Idecabtagene Vicleucel in relapsed and refractory multiple myeloma. *New England Journal of Medicine*. 2021;384(8):705-16. Available from: <http://doi:10.1056/NEJMoa2024850>.
14. Rodriguez-Otero P, Ailawadhi S, Arnulf B, et al. Ide-Cel or standard regimens in relapsed and refractory multiple myeloma. *New England Journal of Medicine*. 2023; 388(11):1002-14. Available from: <http://doi:10.1056/NEJMoa213614>.
15. Moreau P, Garfall AL, van de Donk NWCJ, et al. Teclistamab in relapsed or refractory multiple myeloma. *New England Journal of Medicine*. 2022; 387(6): 495-505. Available from: <http://doi:10.1056/NEJMoa2203478>.
16. Lesokhin AM, Tomasson MH, Arnulf B, et al. Elranatamab in relapsed or refractory multiple myeloma: Phase 2 MagnetisMM-3 Trial results. *Nature Medicine*. 2023; 29(9): 2259-67. Available from: <http://doi:10.1038/s41591-023-02528-9>.
17. Cohen AD, Garfall AL, Stadtmaue EA, et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. *The Journal of Clinical Investigation*. 2022;129(6):2210-21. Available from: <http://doi:10.1172/JCI126397>.
18. Van Oekelen O, Aleman A, Upadhyaya B, et al. Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. *Nature Medicine*. 2021;27(12):2099-2103. Available from: <http://doi:10.1038/s41591-021-01564-7>.
19. Chari A, Minnema MC, Berdeja JG, et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. *New England Journal of Medicine*. 2022;387(24):2232-44. Available from: <http://doi:10.1056/NEJMoa2204591>.
20. Hayden PJ, Roddie C, Bader P, et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for BMT and the JACIE and EHA. *Ann Oncol*. 2022 Mar;33(3):259-275.
21. Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. *Biology of Blood and Marrow Transplantation: Journal of the American Society for BMT* 2019; 25(4): 625-38. Available from: <http://doi:10.1016/j.bbmt.2018.12.758>.
22. Yakoub-Agha I, Chabannon C, Bader P, et al. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation and the Joint Accreditation Committee of ISCT and EBMT. *Haematologica*. 2020;105(2):297-316. Available from: <http://doi:10.3324/haematol.2019.229781>.
23. Searle E, Quach H, Wong SW, et al. Teclistamab in combination with subcutaneous daratumumab and lenalidomide in patients with multiple myeloma: Results from one cohort of MajesTEC-2, a Phase1b, multicohort study. *Blood*. 2022;140(Supplement 1):394-96. Available from: <http://doi:10.1182/blood-2022-159711>.
24. D'Souza A, Costa LJ, San Miguel JF, et al. Teclistamab, daratumumab, and pomalidomide in patients with relapsed/refractory multiple myeloma: Results from the MajesTEC-2 Cohort a and Trimm<sup>2</sup> Studies. *Blood*. 2024;144(Supplement 1):495; Available from: <http://doi.org/10.1182/blood-2024-200181>.
25. Raab MS, Weinhold N, Kortüm M, et al. Phase 2 study of teclistamab-based induction regimens in patients with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial. *Blood*. 2024;144 (Supplement 1):493. Available from: <http://doi.org/10.1182/blood-2024-206003>.
26. Zamagni E, Silzle T, Špička I, et al. Phase 3 study of teclistamab (Tec) in combination with lenalidomide (Len) and tec alone versus len alone in NDMM as maintenance therapy following ASCT: Safety run-in results from the MajesTEC-4/EMN30 Trial. *Blood* 2024; 144 (Supplement 1): 494.
27. Prince HM, Bahlis NJ, Rodriguez-Otero P, et al. MagnetisMM-3: Long-term update and efficacy and safety of less frequent dosing of elranatamab in patients with relapsed or refractory multiple myeloma. *Blood*. 2024;144(Supplement 1):4738. Available from: <http://doi.org/10.1182/blood-2024-208192>.
28. Tomasson M, Iida S, Niesvizky R, et al. Long-term efficacy and safety of elranatamab monotherapy in the phase 2 MagnetisMM-3 Trial in relapsed or refractory multiple myeloma (RRMM). *Blood*. 2023;142(Supplement 1):3385. Available from: <http://doi:10.1182/blood-2023-182130>.
29. Pianko M, Pawlyn C, Huang SY, et al. MagnetisMM-9: Efficacy and safety of step-up priming doses and longer dosing intervals of elranatamab (ELRA) in patients with relapsed or refractory multiple myeloma (RRMM). *Blood*. 2024;144 (Supplement 1): 4743. Available from: <http://doi.org/10.1182/blood-2024-205872>.
30. Tomasson MH, Gabayan E, Ali SA, et al. Efficacy of elranatamab (ELRA) in combination with carfilzomib (CFZ) and dexamethasone (DEX) in the phase 1 b MagnetisMM-20 Trial in relapsed or refractory multiple myeloma (RRMM). *Blood*. 2024;144 (Supplement 1):1024. Available from: <http://doi.org/10.1182/blood-2024-210520>.
31. Bumma N, Richter J, Jagannath S, et al. Linvoseltamab for treatment of relapsed/refractory multiple myeloma. *Journal of Clinical Oncology*. 2024;42(22):2702-12. Available from: <http://doi:10.1200/JCO.24.01008>.
32. Rodriguez Valdes C, Voorhees PM, D'Souza A, et al. Efficacy, safety, and determination of RP2D of ABBV-383, a BCMA bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM). *Journal of Clinical Oncology*. 2024;42(16\_suppl):7531-7531. Available from: [http://doi:10.1200/JCO.2024.42.16\\_suppl.7531](http://doi:10.1200/JCO.2024.42.16_suppl.7531).
33. Rodriguez C, Mielnik M, Kazandjian D, et al. ABBV-383 plus daratumumab-dexamethasone in relapsed or refractory multiple myeloma: A phase 1 b dose-escalation and safety expansion study. *Blood*. 2024;144(Supplement 1):496; Available from: <http://doi.org/10.1182/blood-2024-205083>.
34. Matous J, Biran N, Perrot A, et al. Talquetamab + pomalidomide in patients with relapsed/refractory multiple myeloma: Safety and preliminary efficacy results from the phase 1 b MonumentAL-2 Study. *Blood*. 2023;142(Supplement 1):1014. Available from: <http://doi:10.1182/blood-2023-187706>.
35. Nooka A, Cochrane T, D'Souza A, et al. Talquetamab, a GPRC5D×CD3 bispecific antibody, in combination with daratumumab and lenalidomide in patients with newly diagnosed multiple myeloma: Safety and efficacy results from the phase 1 b Monumental-2 study. *Blood*. 2024;144(Supplement 1):1975. Available from: <http://doi.org/10.1182/blood-2024-199773>.
36. Cohen YC, Magen H, Gatt ME, et al. Talquetamab plus teclistamab in relapsed or refractory multiple myeloma. *N Eng J Med*. 2025;392(2):138-149. Available from: <http://doi:10.1056/NEJMoa2406536>.
37. Carlo-Stella C, Mazza R, Manier S, et al. RG6234, a GPRC5D×CD3 T-cell engaging bispecific antibody, is highly active in patients with RRMM: Updated intravenous and first subcutaneous results from a Phase I dose-escalation study. *Blood*. 2022;140(Supplement 1):397-399.
38. Richter J, Thomas SK, Krishnan AY, et al. Cevostamab in patients with heavily pretreated RRMM. Results from an ongoing phase I study demonstrate clinically meaningful activity and manageable safety and inform the doses and regimen for combination studies. *Blood*. 2024;144(Supplement 1):1021. Available from: <http://doi.org/10.1182/blood-2024-199542>.
39. Kumar S, Berdeja J, Sborov D, et al. Cevostamab in patients with RRMM who are triple-class refractory and have received a prior BCMA-targeted ADC or CAR T-cell: Initial results from Phase I/II CAMMA 2 study. *EHA Library Facon*; 422314(2024);S210. Available from: <https://library.ehaweb.org/eha/2024/eha2024-congress/422314/shaji.kumar.cevostamab.in.patients.with.rrmm.who.are.triple-class.refractory.html>.

Další literatura u autora  
na [www.casopisvnitrnilekarstvi.cz](http://www.casopisvnitrnilekarstvi.cz)